Hello my dears,
DER AKTIONÄR has now also discovered my portfolio stock Camurus. That's why I'm staying invested.
Perhaps the editors will also read my posts.
The article from DER AKTIONÄR highlights the Swedish biotech company Camurus as a current "top pick" and highlights its strategic partnership with the US pharmaceutical giant Eli Lilly.
🔍 Key messages of the article
- Volatile share price performanceCamurus shares have fluctuated considerably in recent months, but are currently moving significantly upwards again (+4.22%).
- Analyst optimism: The experts at ABG Sundal Collier see considerable potential and are confident that the share will reach new highs.
- Strategic partnership: The cooperation with Eli Lilly is seen as a door opener for new market opportunities and dimensions.
- Key market figures:
- Share price: € 65.50
- Market capitalization: € 3.79 billion
- P/E RATIO: 51
- Performance: +23.23 % year-on-year
- RecommendationDER AKTIONÄR sees good reasons for an investment and points to the long-term growth story.
AKTIONÄR-Tipp Camurus: "Top-Pick" – mit Eli Lilly in neue Dimensionen - DER AKTIONÄR
